Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 45%
filed 2026-06-24
Item 8.01
The filing discloses the consummation of Yorkville International Capital Corp.'s IPO on June 17, 2026, generating $230 million in gross proceeds from the sale of 23 million units at $10.00 per unit, plus a concurrent private placement of 6.3 million warrants for $6.3 million. While this is clearly a material capital-raising event affecting a reasonable investor's assessment of the registrant, it does not fit neatly into the standard 8-K taxonomy. The event is neither a traditional earnings release, M&A activity, debt issuance, nor dilutive equity issuance in the conventional sense (the IPO itself is the primary capital event, not a secondary offering). The company is a SPAC with no operating business, making traditional financial event categories inapplicable. The domain is clearly financial/capital-related, but no specific category captures an IPO consummation disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-24
Item 1.01
The disclosure centers on Consolidated Water's entry into a new 25-year water utility license with the Cayman Islands regulator (OfReg), effective August 1, 2026. While this is a material definitive agreement under Item 1.01, it is fundamentally an operational and regulatory milestone rather than a traditional M&A transaction, debt issuance, or other specifically-named event type. The filing explicitly notes that the new license "establishes a long-term regulatory framework" following years of negotiation, and the Company's pro forma estimates indicate the new rate structure will reduce revenues by approximately $2.1–$2.6 million annually—a material impact on the registrant's core business operations and cash flows.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-24
Item 1.01
Definium entered into an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00 per share, with underwriters exercising their full option for an additional 3,088,235 shares, generating approximately $805 million in gross proceeds. This registered public offering will dilute existing shareholders materially.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-24
Item 1.01
Spring Valley Acquisition Corp. III issued an unsecured promissory note in the principal amount of up to $1,500,000 to its sponsor on June 23, 2026. This is a creation of a direct financial obligation under Item 2.03, constituting a debt issuance. The note is material as it represents a significant financing arrangement for a SPAC, even though it is unsecured and non-interest-bearing, and includes a conversion feature into warrants upon the company's initial business combination.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-24
EX-99.1
This is a comprehensive technical report on the Gaocheng Silver-Lead-Zinc Project prepared by SRK Consulting for Silvercorp Metals Inc., effective December 31, 2025. The report covers mineral resource and reserve estimates, mining methods, processing, environmental permitting, capital and operating costs, and economic analysis. While technical reports are standard industry practice for mining operations, this document discloses material operational and financial information about the project's reserves, resources, and economic viability that would be relevant to investors assessing the registrant's asset base and future production capacity. It does not fit neatly into periodic financial reporting (which would be a 10-K or 10-Q equivalent) but rather represents a detailed operational and technical assessment of a material mining asset.
View raw filing on EDGAR →
RH
(RH)
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of RH's annual shareholder meeting held on June 18, 2026. The filing presents voting results for four proposals: election of three Class II directors (Hilary Krane, Katie Mitic, Ali Rowghani), advisory approval of named executive officer compensation, frequency of Say-on-Pay votes (approved for annual frequency), and ratification of PricewaterhouseCoopers LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-24
Item 8.01
The filing discloses that Femasys has regained compliance with Nasdaq Listing Rule 5550(a)(2) following a minimum bid price deficiency notice issued on July 16, 2025. While the company has now cured the deficiency through a 1-for-20 reverse stock split completed June 5, 2026, the core event is the resolution of a delisting risk that previously threatened the company's continued listing on Nasdaq. This is material to investors as it directly affects the company's ability to remain publicly traded.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-24
Item 8.01
Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026, based on positive Phase 3 CORE and CORE2 trial results. This represents the company's first independent commercial launch in a prevalent disease and a significant regulatory milestone for its novel RNA-targeted therapy platform.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
This Item 5.07 disclosure reports the final voting results from Femasys Inc.'s Annual Meeting of Stockholders held on June 24, 2026. The filing presents detailed vote tallies for two proposals: (1) election of two Class II directors (Charles Larsen and Kenneth Eichenbaum) and (2) ratification of KPMG LLP as the independent registered accounting firm. Both proposals passed with substantial majorities. This is a routine but material shareholder vote result disclosure required by Item 5.07 of Form 8-K.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-24
EX-99.1
Global Ship Lease announced entry into newbuilding contracts for five containerships with an aggregate purchase price of approximately $413 million, scheduled for delivery within 2029 and contracted on multi-year charters. This represents a material capital commitment and acquisition of assets that would affect a reasonable investor's assessment of the company's fleet composition, cash generation capacity, and strategic direction. The announcement explicitly references these as additions to the company's "overall newbuilding orderbook to 15 ships" expected to generate over $1.0 billion in Adjusted EBITDA.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-24
Item 1.01
Teradata entered into a new $400 million unsecured revolving credit facility with Bank of America on June 24, 2026, replacing a prior 2022 credit agreement. The new facility has a five-year term with customary covenants and represents a material refinancing of the company's capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
CarMax held its Annual Meeting of Shareholders on June 23, 2026, with voting results including election of directors, ratification of KPMG LLP as auditors, approval of the executive compensation advisory resolution, and approval of amendments to the 2002 Stock Incentive Plan.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-24
Item 2.02
NOVAGOLD issued a press release on June 24, 2026 announcing financial results for the fiscal quarter ended May 31, 2026, disclosing net loss of ($25.5) million, earnings per share of ($0.06), cash position of $370.2 million, and operational cash expenditures of $22.7 million. The filing explicitly states "Details of the financial results for the quarter ended May 31, 2026 are presented in the consolidated financial statements and quarterly report on Form 10-Q filed on June 24, 2026," confirming this is a quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-24
EX-99.1
The exhibit discloses results of an annual and special meeting of shareholders held on June 23, 2026, including voting outcomes on four resolutions: election of seven directors (Resolution #1), re-appointment of PricewaterhouseCoopers LLP as auditor (Resolution #2), approval of registered office relocation from Québec to Ontario (Resolution #3), and approval of a name change to "Osisko Gold Group Inc." (Resolution #4). The press release presents detailed vote tallies and percentages for each resolution, which is the core disclosure required under Item 5.07 of Form 8-K (and analogous 6-K disclosure). The company also granted 247,129 deferred share units to independent directors as part of annual compensation review, which is ancillary to the shareholder vote disclosure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-24
EX-99.1
The exhibit discloses voting results from Taseko's 2026 Annual General Meeting held June 24, 2026, including shareholder approval of a name change to Trekor Metals Limited (effective June 25, 2026), director elections, and amendments to the deferred share unit plan. The disclosure of specific vote percentages for each director nominee and approval of the name change constitutes a shareholder_vote_results event. The name change is material as it affects the company's identity and trading information across multiple exchanges (TSX, NYSE American, LSE).
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-24
MIND CTI Ltd. received a Nasdaq letter on June 23, 2026 indicating non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)) requiring a minimum of $1 per share. The company has 180 calendar days until December 21, 2026 to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status and investor assessment.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-24
EX-99.1
InMode received an unsolicited merger proposal from MN Business Strategy (a group including co-founder and CEO Moshe Mizrahy) to acquire all outstanding shares not already owned by the bidder at $16.20 per share in cash. The Board has formed a special committee to evaluate the proposal. This is a material M&A activity disclosure under Item 1.01 (entry into a material acquisition or change of control), as it involves a potential merger that would materially affect the company's structure and shareholder interests.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-24
This is a disclosure of shareholder vote results from Nomura Holdings' 122nd Annual General Meeting held on June 23, 2026. The exhibit reports the voting outcomes for the appointment of 11 directors (Koji Nagai, Kentaro Okuda, Yutaka Nakajima, Shoji Ogawa, Victor Chu, Patricia Mosser, Takahisa Takahara, Miyuki Ishiguro, Masahiro Ishizuka, Taku Oshima, and Nellie Liang), with detailed vote counts and approval ratios for each nominee. All 11 director appointments were approved. This is a material governance event affecting the composition of the board of a major financial institution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-24
Item 8.01
Prologis announced an indicative all-share acquisition proposal for SEGRO plc on June 24, 2026, following a June 16 letter setting out terms for an all-stock transaction. Although SEGRO's board rejected the proposal on June 23, the announcement of a material acquisition attempt—coupled with Prologis' stated intention to potentially make a firm offer by July 22, 2026 under UK takeover rules—constitutes a disclosure of M&A activity that would materially affect investor assessment of both parties.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 94%
filed 2026-06-24
EX-99.1
Bilibili announced authorization of a new $300 million share repurchase program by its board of directors, effective immediately for the next 24 months. This represents a material capital return commitment to shareholders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-24
Item 1.01
CalciMedica entered into a First Amendment to its Loan and Security Agreement on June 23, 2026, materially modifying the terms of a $10,000,000 debt facility by extending the interest-only period and maturity date by one year, increasing the final payment fee by $200,000, and significantly expanding conversion rights from $1,000,000 to $3,000,000 of principal into common stock or pre-funded warrants.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
This is a clear disclosure of shareholder vote results from MapLight Therapeutics' 2026 annual meeting held on June 23, 2026. The filing reports voting outcomes for two proposals: (1) election of three directors (Martin Babler, Troy Cox, and George Pavlov), all of whom were elected, and (2) ratification of RSM US LLP as the independent auditor for fiscal year 2026, which passed with overwhelming support. This is a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-24
Item 8.01
The filing discloses a material acquisition transaction: Emerald Holding, Inc. entered into an Agreement and Plan of Merger with Apollo-managed funds on May 9, 2026, with Merger Sub to merge into Emerald, making Emerald a wholly-owned subsidiary of Parent. The press release confirms the transaction is expected to close in the second half of 2026 and announces leadership changes (Paul Miller as CEO of the combined entity, Hervé Sedky transitioning to senior advisor), which are ancillary to the primary M&A event. This is a change of control transaction material to any reasonable investor.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-06-24
Item 2.02
This is a clear earnings release disclosing Paychex's financial results for the fourth quarter and full fiscal year 2026 ended May 31, 2026. The press release reports total revenue of $6.5 billion (17% growth), operating income of $2.5 billion (14% growth), and diluted EPS of $4.89 (7% growth) for the full year, along with detailed quarterly comparisons and forward guidance for fiscal 2027. The disclosure is furnished under Item 2.02 and attached as Exhibit 99.1, which is the standard format for earnings releases in 8-K filings.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-24
EX-99.1
Sanofi announced regulatory approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment, representing the second global approval for this formulation and a significant commercial milestone for the company's oncology portfolio.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-24
EX-99.2
Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research & Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-24
EX-99.3
European Commission approved Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, representing a significant regulatory and commercial milestone for Sanofi's neurology pipeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-24
EX-99.4
Sanofi announced regulatory approval of Wayrilz (rilzabrutinib) in Japan for treating immune thrombocytopenia (ITP), based on successful LUNA 3 phase 3 clinical trial results, enabling market entry for this novel therapeutic.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-06-24
Item 2.01
Eli Lilly and Company, through subsidiary LDH XV Corporation, completed the acquisition of all issued and outstanding ordinary shares of Centessa Pharmaceuticals plc via a court-sanctioned scheme of arrangement under UK law on June 24, 2026, for $38.00 per share in cash plus contingent value rights of up to $9.00 per share, resulting in Centessa becoming a wholly owned subsidiary of Lilly and a complete change of control.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-24
Item 8.01
The filing discloses an ongoing private placement offering of up to $2.165 billion of common shares across multiple classes, with $534.084 million already raised as of May 31, 2026. This represents a substantial unregistered equity issuance that would dilute existing shareholders. While the filing also mentions dividend declarations and DRIP activity, the primary material event disclosed in Item 8.01 is the status and scale of the continuous private offering, which is a classic dilutive issuance event material to investors.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-24
Item 8.01
The Board of Trustees approved a material change to the Fund's 80% investment policy effective August 28, 2026, broadening the definition of eligible investments to include "income-producing investments" beyond traditional corporate debt, and expanding the types of instruments that may be counted toward the policy. This is a governance decision affecting the Fund's fundamental investment mandate and requires 60-day shareholder notice, making it material to investors' understanding of the Fund's strategy and operations.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-24
Item 8.01
The Board of Trustees approved a material change to the Fund's 80% investment policy effective August 28, 2026, broadening the definition of eligible investments to include income-producing investments beyond corporate debt obligations. This is a governance event—a board-approved policy amendment affecting the Fund's investment mandate—that would materially affect investor expectations about the Fund's portfolio composition and risk profile. While not a named governance category (such as an executive appointment or auditor change), it clearly falls within governance-related matters requiring board approval and shareholder notification.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-24
Item 8.01
The Board of Trustees approved a change to the Fund's 80% investment policy effective August 28, 2026, expanding the definition of eligible investments to include a broader range of income-producing instruments and fixed income securities. This is a material governance and policy amendment affecting the Fund's investment mandate and strategy, disclosed under Item 8.01 (Other Events). While not a named governance category (such as an executive appointment or auditor change), it represents a significant policy decision by the board that would affect investor expectations about the Fund's portfolio composition and risk profile.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-24
Item 8.01
The filing discloses a material change to the Fund's investment guidelines effective July 24, 2026, permitting unlimited investment in commercial mortgage-related securities and allowing up to 50% of assets in below-investment-grade debt. This is a governance/policy matter affecting the Fund's permitted investment scope and risk profile, which would materially affect investor assessment of the Fund's strategy and risk exposure. While not a traditional governance event (board action, executive change, or shareholder vote), it represents a significant policy change that falls under governance_other as a material fund governance disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
The Fund disclosed material changes to its investment strategy effective June 24, 2026 and July 24, 2026, permitting it to invest in and/or originate loans (including residential/commercial real estate, consumer loans, and other types) and to invest without limitation in defaulted bonds. These are significant expansions of the Fund's principal investment strategies that would materially affect investor expectations regarding portfolio composition, risk profile, and asset allocation, warranting disclosure under Item 8.01 as a strategic policy change.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
PIMCO High Income Fund disclosed a material change to its principal investment strategy, effective June 24, 2026, permitting the Fund to invest in and/or originate loans (including residential/commercial real estate, consumer loans, and bank loans without limitation as of July 24, 2026). This is a significant operational and strategic shift in the Fund's permitted investment scope, disclosed via prospectus supplement. While not a traditional M&A, debt issuance, or financial event, this represents a material change to the Fund's investment mandate and risk profile that would affect investor decision-making.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
The Fund disclosed material changes to its principal investment strategy effective June 24, 2026 and July 24, 2026, permitting it to invest in and/or originate loans (including subprime loans) and to invest without limitation in defaulted bonds. These are significant operational and strategic expansions of the Fund's investment mandate that would affect a reasonable investor's assessment of the Fund's risk profile and investment approach, disclosed via prospectus supplement (Exhibit 99.1).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
The Fund disclosed a material change to its principal investment strategy effective June 24, 2026, permitting it to invest in and/or originate loans (residential, commercial, consumer, etc.) as a core strategy. This is a significant operational and strategic shift disclosed via prospectus supplement, affecting the Fund's investment mandate and risk profile. While not fitting a specific named category, this is clearly an operational/strategic business event material to investors in the Fund.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-24
Item 8.01
The Fund disclosed a material change to its principal investment strategy, effective June 24, 2026, to permit investment in and/or origination of loans (residential, commercial, consumer, etc.). This is a significant operational and strategic shift in the Fund's permitted activities, disclosed via prospectus supplement. While not fitting the specific categories of M&A, debt issuance, or other named financial events, this represents a material change to the Fund's investment mandate and risk profile that would affect investor decision-making.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-24
Item 7.01
The Board of Trustees declared a regular monthly distribution to shareholders of Oaktree Strategic Credit Fund on June 23, 2026, specifying gross and net distribution amounts per share across four share classes (Class I, D, S, and T), with a record date of June 26, 2026 and payment date of July 29, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-24
Item 8.01
The Fund disclosed its monthly NAV per share ($22.41 as of May 31, 2026), aggregate NAV (~$4.5 billion), portfolio fair value (~$6.9 billion), debt levels (~$2.8 billion), and leverage ratio (0.60x), along with the status of ongoing public and private share offerings.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-24
Item 3.01
Definitive Healthcare received written notice from Nasdaq on June 18, 2026, that it failed to meet the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days until December 15, 2026, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-24
Item 1.01
Chewy entered into a new $600 million seven-year senior secured term loan credit facility on June 23, 2026, and amended its existing ABL Credit Agreement to extend maturity to June 23, 2031, creating material direct financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-06-24
Item 2.03
Oncor completed a sale of A$750 million (approximately US$525 million) of 5.70% Senior Secured Notes due June 24, 2033 on June 24, 2026. This is a clear creation of a direct financial obligation through debt issuance, disclosed under Item 2.03. The notes are secured by a lien on Oncor's transmission and distribution property and carry customary events of default, making this a material capital-raising event for the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Kymera's Annual Meeting of Shareholders held on June 24, 2026. The filing reports the final voting tallies for three proposals: election of Class III directors (Bruce Booth, Nello Mainolfi, John Maraganore, and Elena Ridloff), non-binding advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a material governance event affecting the composition of the board and auditor ratification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-24
Item 2.03
The Company increased commitments under its senior secured revolving credit facility with Sumitomo Mitsui Banking Corporation from $140 million to $165 million and increased the maximum principal amount from $310 million to $335 million. This amendment to an existing credit facility creates or expands a direct financial obligation, which is the hallmark of debt_issuance under Item 2.03. The increase in available borrowing capacity is material to a BDC's financing flexibility and capital structure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-24
Item 8.01
The filing discloses the declaration of a second quarter 2026 supplemental dividend of $0.03 per share, payable on July 13, 2026 to shareholders of record as of June 26, 2026. This is a clear dividend distribution event. As a BDC, dividend distributions are material to shareholders and affect the total return profile of the investment.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-24
Item 1.01
Stanley Black & Decker entered into two material credit facilities on June 18, 2026: a $1.0 billion 364-Day Credit Agreement and a $2.0 billion Amended and Restated Five Year Credit Agreement, representing the creation of $3.0 billion in committed credit capacity. The prior 364-Day Credit Agreement dated June 23, 2025 was terminated in connection with the new facility, constituting a refinancing of the company's credit arrangements.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-24
Item 8.01
Western Union amended its Delayed Draw Term Loan Credit Agreement on June 17, 2026, extending the Commitment Period from July 8, 2026 to November 10, 2026. This is a material amendment to an existing credit facility that extends the company's borrowing window, affecting its financial flexibility and capital structure. While it does not fit the specific categories of debt_issuance (which typically covers new debt creation) or covenant_breach, it is clearly a material financial event involving modification of a direct financial obligation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-24
Item 5.07
This is a clear disclosure of shareholder vote results from Disc Medicine's 2026 Annual Meeting of Stockholders held on June 18, 2026. The filing reports voting outcomes on three proposals: election of Class III directors (Donald Nicholson, John Quisel, and William White), advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →